Comparative Pharmacology

Head-to-head clinical analysis: DEXTROSE 50 IN PLASTIC CONTAINER versus DEXTROSE 60.

Peer-Reviewed Evidence

Differential Analysis

DEXTROSE 50% IN PLASTIC CONTAINER vs DEXTROSE 60%

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

DEXTROSE 50% IN PLASTIC CONTAINER

Intravenous Hypertonic Dextrose Solution

Category C

DEXTROSE 60%

Intravenous Hypertonic Dextrose Solution

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Dextrose is a monosaccharide that serves as a source of energy for the body. It is rapidly metabolized to produce glucose, which is essential for cellular metabolism. Intravenous administration increases blood glucose levels, providing calories and correcting hypoglycemia.

Dextrose is a monosaccharide that provides a source of calories and hydration. It increases blood glucose levels and is metabolized to carbon dioxide and water, yielding energy.

Clinical Dosing

Intravenous administration of 25 g (50 mL of 50% solution) for hypoglycemia; may repeat as needed. For hyperkalemia, administer 25 g (50 mL) with 10 units of regular insulin intravenously. Continuous infusion for parenteral nutrition is 5-25 g per liter of total nutrient admixture, rate based on glucose tolerance.

Intravenous: For hypoglycemia, 0.5-1 g/kg (10-25 g) as 50% solution; for hyperkalemia, 25 g dextrose with 10 units regular insulin IV. For parenteral nutrition, variable per metabolic needs. Infusion rate not to exceed 0.5 g/kg/h.

Direct Interaction

None Documented